CRISPR Therapeutics AG (CRSP) Accumulated Expenses (2015 - 2026)

CRISPR Therapeutics AG has disclosed Accumulated Expenses across 12 years of filings, most recently posting $70.3 million for Q2 2026.

• In Q2 2026, Accumulated Expenses fell 4.69% year-over-year to $70.3 million; the TTM figure through Jun 2026 stood at $70.3 million (down 4.69% YoY), while the FY2025 annual figure was $89.4 million, up 117.68% from the prior year.
• Accumulated Expenses came in at $70.3 million for Q2 2026 at CRISPR Therapeutics AG, down from $74.9 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $103.0 million in Q3 2022 to a low of $41.1 million in Q4 2024.
• Average Accumulated Expenses over 5 years is $75.4 million, with a median of $77.1 million recorded in 2022.
• Year-over-year, Accumulated Expenses plunged 41.64% in 2023 and soared 117.68% in 2025.
• Over 5 years, Accumulated Expenses stood at $77.7 million in 2022, then sank by 41.64% to $45.3 million in 2023, then dropped by 9.4% to $41.1 million in 2024, then surged by 117.68% to $89.4 million in 2025, then fell by 21.4% to $70.3 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $70.3 million in Q2 2026, $74.9 million in Q1 2026, and $89.4 million in Q4 2025.